Table 2.
Accordance of mutations in tumor biopsies and plasma ctDNA by VAF
| Patient | Mutations | Tissue | Blood | ||
|---|---|---|---|---|---|
| Baseline | Baseline | Follow-up 9 weeks | Follow-up 18 weeks | ||
| 005 | TP53 c.524G>A | 28% | 2% | < 1% | 6%a |
| FBXW7 c.1177dupA | – | 9% | < 1% | – | |
| 013 | TP53 c.743G > A | 44% | 13% | < 1% | < 1% |
| 023 | KRAS c.35G > A | – | – | – | 11% |
| 034 | TP53 c.380C > T | 11% | – | – | – |
| KRAS c.35G > A | – | 2% | – | – | |
| 039 | TP53 c.743G > A | 4.65% | 5% | < 1% | < 1% |
| CDKN2A c.35C > T | – | 1% | < 1% | – | |
| 040 | TP53 c.839G > A | 2.40% | 12% | – | 1%a |
| TP53 c.844C > T | 19% | < 1% | – | – | |
| 042 | TP53 c.916C > T | 83% | 13% | < 1% | 2% |
aSamples drawn at time of progression on CT evaluation